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Cognitive dysfunction among newly diagnosed older patients with hematological 
malignancy: frequency, clinical indicators, and predictors  
 
Background 
Medical staffs often overlook or underestimate the presence or severity of cognitive 
dysfunction, which causes various problems including caregiver burden and patient 
survival. The purpose of this study was to clarify the frequency, clinical indicators, and 
predictors of cognitive dysfunction among newly diagnosed older patients with 
hematologic malignancy receiving first-line chemotherapy. 
 
Methods 
Patients aged 65 years or over with a primary diagnosis of malignant lymphoma or 
multiple myeloma were consecutively recruited. Cognitive dysfunction was evaluated 
using the Mini-Mental State Examination (MMSE) twice: before starting chemotherapy 
(T1) and one month later (T2). We estimated the frequency of cognitive dysfunction based 
on MMSE scores (cut-off score; 23/24). Participants also underwent a comprehensive 
geriatric assessment at T1. Clinical indicators that were associated with cognitive 
dysfunction were explored via cross-sectional analysis at T1. Predictors of cognitive 
dysfunction at T2 were also investigated among patients without cognitive dysfunction 
at T1. 
 
Results 
A total of 145 patients participated in the study; cognitive dysfunction at T1 was present 
in 20%. Multivariate analysis demonstrated that lower educational attainment and 
poorer instrumental activities of daily living were significant clinical indicators. 7% of 
participants without cognitive dysfunction at T1 predicted significantly new-onset 
cognitive dysfunction at T2. The only predictor was subjective perception of difficulty 
remembering at T1.  
 
Conclusions 
The prevalence rate of cognitive dysfunction was non-negligible among older patients 
with hematologic malignancy. Attention to the clinical indicators and predictors found in 
this study may provide facilitate the identification of cognitive dysfunction in patients 
with cancer. 
 
